<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Alkermes Plc — News on 6ix</title>
<link>https://6ix.com/company/alkermes-plc</link>
<description>Latest news and press releases for Alkermes Plc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 21 Apr 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/alkermes-plc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835454278dffbe2df0e27b6.webp</url>
<title>Alkermes Plc</title>
<link>https://6ix.com/company/alkermes-plc</link>
</image>
<item>
<title>Alkermes to Report First Quarter Financial Results on May 5, 2026</title>
<link>https://6ix.com/company/alkermes-plc/news/alkermes-to-report-first-quarter-financial-results-on-may-5-2026</link>
<guid isPermaLink="true">https://6ix.com/company/alkermes-plc/news/alkermes-to-report-first-quarter-financial-results-on-may-5-2026</guid>
<pubDate>Tue, 21 Apr 2026 20:05:00 GMT</pubDate>
<description>DUBLIN, April 21, 2026--Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, May 5, 2026 to discuss the company’s first quarter financial results.</description>
</item>
<item>
<title>Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting</title>
<link>https://6ix.com/company/alkermes-plc/news/alkermes-to-present-additional-data-from-vibrance-1-phase-2-study-of-alixorexton-in-patients-with-narcolepsy-type-1-at-the-american-academy-of-neurology-aan-2026-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/alkermes-plc/news/alkermes-to-present-additional-data-from-vibrance-1-phase-2-study-of-alixorexton-in-patients-with-narcolepsy-type-1-at-the-american-academy-of-neurology-aan-2026-annual-meeting</guid>
<pubDate>Thu, 16 Apr 2026 11:00:00 GMT</pubDate>
<description>DUBLIN, April 16, 2026--Alkermes plc (Nasdaq: ALKS) today announced plans to present new data from the Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1) at the American Academy of Neurology (AAN) 2026 Annual Meeting, taking place April 18-22, 2026 in Chicago. Alixorexton is a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of NT1, narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH).</description>
</item>
<item>
<title>Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry</title>
<link>https://6ix.com/company/alkermes-plc/news/findings-from-long-term-analysis-of-the-effects-of-lybalvir-olanzapine-and-samidorphan-on-negative-symptoms-of-schizophrenia-published-in-the-journal-of-clinical-psychiatry</link>
<guid isPermaLink="true">https://6ix.com/company/alkermes-plc/news/findings-from-long-term-analysis-of-the-effects-of-lybalvir-olanzapine-and-samidorphan-on-negative-symptoms-of-schizophrenia-published-in-the-journal-of-clinical-psychiatry</guid>
<pubDate>Tue, 14 Apr 2026 11:00:00 GMT</pubDate>
<description>DUBLIN, April 14, 2026--Alkermes plc (Nasdaq: ALKS) today announced the publication of a 56-week post hoc analysis of the effects of LYBALVI® (olanzapine and samidorphan) on negative symptoms in adults living with schizophrenia in the peer-reviewed publication The Journal of Clinical Psychiatry. The analysis—titled "The Efficacy of Olanzapine/Samidorphan on Negative Symptoms: A Post Hoc Analysis of 56-Week Treatment in Patients With Schizophrenia"—found that treatment with LYBALVI was associated</description>
</item>
<item>
<title>Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2</title>
<link>https://6ix.com/company/alkermes-plc/news/alkermes-announces-initiation-of-phase-3-brilliance-studies-evaluating-alixorexton-for-the-treatment-of-narcolepsy-type-1-and-type-2</link>
<guid isPermaLink="true">https://6ix.com/company/alkermes-plc/news/alkermes-announces-initiation-of-phase-3-brilliance-studies-evaluating-alixorexton-for-the-treatment-of-narcolepsy-type-1-and-type-2</guid>
<pubDate>Wed, 01 Apr 2026 04:00:00 GMT</pubDate>
<description>DUBLIN--(BUSINESS WIRE)-- Alkermes plc (Nasdaq: ALKS) today announced the initiation of the Brilliance Studies, a phase 3 program evaluating the safety and</description>
</item>
<item>
<title>Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program</title>
<link>https://6ix.com/company/alkermes-plc/news/alkermes-announces-inaugural-alkermes-pathways-apn-research-awardstm-program-4</link>
<guid isPermaLink="true">https://6ix.com/company/alkermes-plc/news/alkermes-announces-inaugural-alkermes-pathways-apn-research-awardstm-program-4</guid>
<pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
<description>— Competitive Grant Program to Offer Individual Grants of Up to $10,000 per Project — — Inaugural Application Cycle Open to Licensed Psychiatric-Mental</description>
</item>
<item>
<title>Alkermes to Present at the Stifel 2026 Virtual CNS Forum</title>
<link>https://6ix.com/company/alkermes-plc/news/alkermes-to-present-at-the-stifel-2026-virtual-cns-forum-15</link>
<guid isPermaLink="true">https://6ix.com/company/alkermes-plc/news/alkermes-to-present-at-the-stifel-2026-virtual-cns-forum-15</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>DUBLIN--(BUSINESS WIRE)-- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Stifel 2026 Virtual CNS</description>
</item>
<item>
<title>Alkermes plc Announces CEO Succession Plan</title>
<link>https://6ix.com/company/alkermes-plc/news/alkermes-plc-announces-ceo-succession-plan</link>
<guid isPermaLink="true">https://6ix.com/company/alkermes-plc/news/alkermes-plc-announces-ceo-succession-plan</guid>
<pubDate>Wed, 25 Feb 2026 05:00:00 GMT</pubDate>
<description>— Richard Pops to Retire from Role of Chief Executive Officer Following Distinguished 35-year Career with Alkermes — — Board of Directors Appointed Blair</description>
</item>
<item>
<title>Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026</title>
<link>https://6ix.com/company/alkermes-plc/news/alkermes-plc-reports-financial-results-for-the-fourth-quarter-and-year-ended-dec-31-2025-and-provides-financial-expectations-for-2026</link>
<guid isPermaLink="true">https://6ix.com/company/alkermes-plc/news/alkermes-plc-reports-financial-results-for-the-fourth-quarter-and-year-ended-dec-31-2025-and-provides-financial-expectations-for-2026</guid>
<pubDate>Wed, 25 Feb 2026 05:00:00 GMT</pubDate>
<description>DUBLIN--(BUSINESS WIRE)-- Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2025 and provided financial</description>
</item>
<item>
<title>Alkermes to Present at the TD Cowen 46th Annual Health Care Conference</title>
<link>https://6ix.com/company/alkermes-plc/news/alkermes-to-present-at-the-td-cowen-46th-annual-health-care-conference</link>
<guid isPermaLink="true">https://6ix.com/company/alkermes-plc/news/alkermes-to-present-at-the-td-cowen-46th-annual-health-care-conference</guid>
<pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
<description>DUBLIN--(BUSINESS WIRE)-- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the TD Cowen 46th Annual Health</description>
</item>
<item>
<title>Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market</title>
<link>https://6ix.com/company/alkermes-plc/news/alkermes-plc-completes-acquisition-avadel-123000023</link>
<guid isPermaLink="true">https://6ix.com/company/alkermes-plc/news/alkermes-plc-completes-acquisition-avadel-123000023</guid>
<pubDate>Thu, 12 Feb 2026 12:30:00 GMT</pubDate>
<description>DUBLIN, February 12, 2026--Alkermes plc (Nasdaq: ALKS) ("Alkermes") and Avadel Pharmaceuticals plc (Nasdaq: AVDL) ("Avadel") today announced Alkermes’ completion of its acquisition of Avadel, a commercial-stage biopharmaceutical company. The acquisition adds Avadel’s FDA-approved product, LUMRYZ®, to Alkermes’ commercial portfolio, and provides Alkermes with a commercial organization experienced in this disease state. This strategic move accelerates Alkermes’ entry into the sleep medicine market</description>
</item>
<item>
<title>Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026</title>
<link>https://6ix.com/company/alkermes-plc/news/alkermes-report-fourth-quarter-end-210000020</link>
<guid isPermaLink="true">https://6ix.com/company/alkermes-plc/news/alkermes-report-fourth-quarter-end-210000020</guid>
<pubDate>Wed, 11 Feb 2026 21:00:00 GMT</pubDate>
<description>DUBLIN, February 11, 2026--Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Wednesday, Feb. 25, 2026 to discuss the company’s fourth quarter and year-end 2025 financial results. Management will also discuss financial expectations for 2026 and provide an update on the company.</description>
</item>
<item>
<title>Alixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1</title>
<link>https://6ix.com/company/alkermes-plc/news/alixorexton-granted-breakthrough-therapy-designation-120000017</link>
<guid isPermaLink="true">https://6ix.com/company/alkermes-plc/news/alixorexton-granted-breakthrough-therapy-designation-120000017</guid>
<pubDate>Tue, 06 Jan 2026 12:00:00 GMT</pubDate>
<description>DUBLIN, January 06, 2026--Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy...</description>
</item>
<item>
<title>Alkermes to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/alkermes-plc/news/alkermes-present-44th-annual-jp-morgan-healthcare-conference-2025-12-30</link>
<guid isPermaLink="true">https://6ix.com/company/alkermes-plc/news/alkermes-present-44th-annual-jp-morgan-healthcare-conference-2025-12-30</guid>
<pubDate>Tue, 30 Dec 2025 05:00:00 GMT</pubDate>
<description>DUBLIN--(BUSINESS WIRE)-- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and</description>
</item>
<item>
<title>Alkermes to Participate in Two Upcoming Investor Conferences</title>
<link>https://6ix.com/company/alkermes-plc/news/alkermes-participate-two-upcoming-investor-conferences-2025-11-25</link>
<guid isPermaLink="true">https://6ix.com/company/alkermes-plc/news/alkermes-participate-two-upcoming-investor-conferences-2025-11-25</guid>
<pubDate>Tue, 25 Nov 2025 05:00:00 GMT</pubDate>
<description>DUBLIN--(BUSINESS WIRE)-- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences. 8th Annual</description>
</item>
<item>
<title>Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc</title>
<link>https://6ix.com/company/alkermes-plc/news/alkermes-plc-announces-increased-offer-acquire-avadel-pharmaceuticals-plc-2025-11-19</link>
<guid isPermaLink="true">https://6ix.com/company/alkermes-plc/news/alkermes-plc-announces-increased-offer-acquire-avadel-pharmaceuticals-plc-2025-11-19</guid>
<pubDate>Wed, 19 Nov 2025 05:00:00 GMT</pubDate>
<description>NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE</description>
</item>
<item>
<title>Alkermes Response to Avadel Announcement</title>
<link>https://6ix.com/company/alkermes-plc/news/alkermes-response-avadel-announcement-2025-11-14</link>
<guid isPermaLink="true">https://6ix.com/company/alkermes-plc/news/alkermes-response-avadel-announcement-2025-11-14</guid>
<pubDate>Fri, 14 Nov 2025 05:00:00 GMT</pubDate>
<description>NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE</description>
</item>
<item>
<title>Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2</title>
<link>https://6ix.com/company/alkermes-plc/news/alkermes-announces-positive-topline-results-vibrance-2-phase-2-study-once-daily</link>
<guid isPermaLink="true">https://6ix.com/company/alkermes-plc/news/alkermes-announces-positive-topline-results-vibrance-2-phase-2-study-once-daily</guid>
<pubDate>Wed, 12 Nov 2025 05:00:00 GMT</pubDate>
<description>– Alixorexton is the First Oral Orexin 2 Receptor Agonist to Demonstrate Efficacy in a Large Phase 2 Study in Patients With Narcolepsy Type 2, Supporting</description>
</item>
<item>
<title>FORM 8.1(a) & (b) (Opening Position Disclosure)</title>
<link>https://6ix.com/company/alkermes-plc/news/form-8-1-b-opening-140000820</link>
<guid isPermaLink="true">https://6ix.com/company/alkermes-plc/news/form-8-1-b-opening-140000820</guid>
<pubDate>Wed, 05 Nov 2025 14:00:00 GMT</pubDate>
<description>Alkermes plc (Nasdaq: ALKS):</description>
</item>
<item>
<title>Avadel Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/alkermes-plc/news/avadel-pharmaceuticals-reports-third-quarter-2025-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/alkermes-plc/news/avadel-pharmaceuticals-reports-third-quarter-2025-financial-results-and-provides-corporate-update</guid>
<pubDate>Tue, 04 Nov 2025 21:01:00 GMT</pubDate>
<description>– Generated LUMRYZ™ net product revenue of $77.5 million, a 55% increase compared to third quarter 2024 – – Approximately 3,400 patients on LUMRYZ as of September 30, 2025, a 48% increase compared to September 30, 2024 – – Announced global settlement of all litigation with Jazz Pharmaceuticals, Inc. (“Jazz”) – – Acquisition by Alkermes plc (“Alkermes”) expected to close in first quarter 2026 – DUBLIN, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutica</description>
</item>
<item>
<title>Alkermes plc Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/alkermes-plc/news/alkermes-plc-reports-third-quarter-2025-financial-results-2025-10-28</link>
<guid isPermaLink="true">https://6ix.com/company/alkermes-plc/news/alkermes-plc-reports-third-quarter-2025-financial-results-2025-10-28</guid>
<pubDate>Tue, 28 Oct 2025 04:00:00 GMT</pubDate>
<description>— Third Quarter Revenues of $394.2 Million — — GAAP Net Income of $82.8 Million and Diluted GAAP Earnings per Share of $0.49 — — Company Raises 2025 Financial</description>
</item>
</channel>
</rss>